Patients and families, academic labs, funders, and foundation leadership — and the timeline of roles and institutions that built the practice across all four.
Every rare-disease engagement touches all four — and most consultants speak fluently to just one. Here's how the work has actually shown up in each.
Foundation CEOs working with pharma partners, major donors, and regulated trials need a CSO who can hold the science and speak the operator's language. Two structured programs added that vocabulary on top of two decades at the bench and in the field.
A three-course business-fluency program — Business Analytics, Economics for Managers, and Financial Accounting — built for professionals who need to operate in business conversations. The vocabulary pharma BD teams, major donors, and foundation boards actually use when the conversation turns to unit economics, pricing, and portfolio decisions.
A four-course PMI-aligned program applied specifically to biotech and drug development: initiation, planning, and execution under regulatory constraint, with a capstone simulating a clinical development cycle. Approved by the Project Management Institute and the UW Foster School of Business.
From the bench to the boardroom — the roles and institutions that built the practice.
Every rare disease program has its own shape. I'd like to understand yours.